The studies that favor this mechanism include those demonstrating that APIs, such as paclitaxel, oxaliplatin, gemcitabine, DXR, 5-fluorouracil, and gemcitabine, to name a few, activate apoptotic pathways that lead to the release of so-called danger signals or danger-associated molecular patterns [DAMPs (e.g., ATP, calreticulin and high-mobility group-B1 protein)] that activate tumor-infiltrating antigen-presenting cells, thereby contributing to immunogenicity of tumor-specific antigens released by dying cancer cells; these studies have been discussed in detail elsewhere (29–31). This evidence concerns the gene HMGB1 and neoplasm.